TCR Engineering & Bispecifics
Sebastian Bunk joined Immatics in 2014 where he is responsible for developing a pipeline of bispecific T cell-engaging receptor (TCER™) molecules. His department is dedicated to generating preclinical proof-of-concept for efficacy, safety and manufacturability of novel TCER™ programs. He has further responsibility in structure-based optimization of T cell receptors (TCRs) for improving their performance in adoptive cell therapy (ACT).
Under Sebastian’s scientific leadership, Immatics established innovative technology for affinity maturation of TCRs and generation of bispecific TCER™ molecules. He is an inventor on 10+ patents related to discovery and engineering of TCRs and bispecific TCER™ programs and has co-authored 10+ publications in peer-reviewed journals.
Sebastian obtained his Ph.D. in Biochemical Pharmacology from the University of Konstanz. Prior to joining Immatics, he worked as Manager at Baxter Innovations in Vienna where he led R&D projects related to different biotherapeutics, such as intravenous immunoglobulin.